-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
5 views
Shares of Sarepta Therapeutics plunged 34% in premarket trading on Monday, a day after the company disclosed a second case of patient death due to acute liver failure after receiving its gene therapy for a rare form of muscular dystrophy.
